In addition to the extra copy of the APP gene leading to an increased penetrance of AD in DS, alterations in the mammalian target of rapamycin (mTOR) cellular signaling pathway may contribute to the increased systemic dysregulations and neurodegeneration seen in persons with DS. The gene discussed is MTOR; the disease is Dravet syndrome.